107 related articles for article (PubMed ID: 16357520)
1. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.
Guo M; Liu S; Herman JG; Zhuang H; Lu F
Cancer Biol Ther; 2006 Feb; 5(2):152-5. PubMed ID: 16357520
[TBL] [Abstract][Full Text] [Related]
2. Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.
Xu Y; Xie Z; Lu H
J Cancer Res Ther; 2018 Jan; 14(1):103-105. PubMed ID: 29516969
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Petty RD; Dahle-Smith A; Stevenson DAJ; Osborne A; Massie D; Clark C; Murray GI; Dutton SJ; Roberts C; Chong IY; Mansoor W; Thompson J; Harrison M; Chatterjee A; Falk SJ; Elyan S; Garcia-Alonso A; Fyfe DW; Wadsley J; Chau I; Ferry DR; Miedzybrodzka Z
J Clin Oncol; 2017 Jul; 35(20):2279-2287. PubMed ID: 28537764
[TBL] [Abstract][Full Text] [Related]
4. Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
Drenckhan A; Grob T; Dupree A; Dohrmann T; Mann O; Izbicki JR; Gros SJ
Langenbecks Arch Surg; 2014 Oct; 399(7):879-88. PubMed ID: 25070024
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro.
Taira N; Doihara H; Oota T; Hara F; Shien T; Takahashi H; Yoshitomi S; Ishibe Y; Shimizu N
Acta Med Okayama; 2006 Feb; 60(1):25-34. PubMed ID: 16508686
[TBL] [Abstract][Full Text] [Related]
7. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
8. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
9. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
Wang WP; Wang KN; Gao Q; Chen LQ
World J Surg Oncol; 2012 Jan; 10():14. PubMed ID: 22252115
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
12. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
13. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Tam IY; Leung EL; Tin VP; Chua DT; Sihoe AD; Cheng LC; Chung LP; Wong MP
Mol Cancer Ther; 2009 Aug; 8(8):2142-51. PubMed ID: 19671738
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
15. Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Saito K; Takigawa N; Ohtani N; Iioka H; Tomita Y; Ueda R; Fukuoka J; Kuwahara K; Ichihara E; Kiura K; Kondo E
Mol Cancer Ther; 2013 Aug; 12(8):1616-28. PubMed ID: 23761220
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Tan DSW; Chong FT; Leong HS; Toh SY; Lau DP; Kwang XL; Zhang X; Sundaram GM; Tan GS; Chang MM; Chua BT; Lim WT; Tan EH; Ang MK; Lim TKH; Sampath P; Chowbay B; Skanderup AJ; DasGupta R; Iyer NG
Nat Med; 2017 Oct; 23(10):1167-1175. PubMed ID: 28920960
[TBL] [Abstract][Full Text] [Related]
17. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
18. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
19. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
[TBL] [Abstract][Full Text] [Related]
20. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
